| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $214.3M | — | +55.5% |
| Cost of Revenue | $20.8M | — | +16.4% |
| R&D Expense | $27.5M | — | +42.2% |
| SG&A Expense | $61.2M | — | +40.5% |
| Operating Income | $29.3M | — | +120.5% |
| Pre-tax Income | $32.7M | — | +110.0% |
| Income Tax | $10.1M | — | +43.6% |
| Net Income | $22.6M | — | +164.6% |
| EPS (Basic) | $0.30 | — | +150.0% |
| EPS (Diluted) | $0.27 | — | +145.5% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $190.0M | +14.7% | +20.9% |
| Short-term Investments | $278.1M | +11.9% | +150.1% |
| Accounts Receivable | $23.2M | +48.9% | -42.0% |
| Inventory | $73.1M | +33.2% | +231.4% |
| Current Assets | $594.2M | +12.7% | +66.9% |
| Total Assets | $825.3M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | $50.2M | — | +124.9% |
| Capital Expenditures | $161K | — | +62.6% |
| Investing Cash Flow | -$31.9M | — | +38.1% |
| Financing Cash Flow | $6.1M | — | +119.4% |
| Free Cash Flow | $50.0M | — | +125.1% |
| +37.7% |
| Current Liabilities | $156.6M | +12.5% | +61.0% |
| Total Liabilities | $219.6M | +12.0% | +54.8% |
| Stockholders' Equity | $605.7M | +6.7% | +32.4% |